FI20011593A - Immunological adjuvant compound - Google Patents

Immunological adjuvant compound Download PDF

Info

Publication number
FI20011593A
FI20011593A FI20011593A FI20011593A FI20011593A FI 20011593 A FI20011593 A FI 20011593A FI 20011593 A FI20011593 A FI 20011593A FI 20011593 A FI20011593 A FI 20011593A FI 20011593 A FI20011593 A FI 20011593A
Authority
FI
Finland
Prior art keywords
novel
immunological adjuvant
compounds
adjuvant compound
adjuvant
Prior art date
Application number
FI20011593A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI120689B (en
Inventor
Lynn D Hawkins
Sally T Ishizaka
Michael Lewis
Pamela Mcguiness
Anneliese Nault
Jeffrey Rose
Daniel P Rossignol
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of FI20011593A publication Critical patent/FI20011593A/en
Application granted granted Critical
Publication of FI120689B publication Critical patent/FI120689B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Abstract

The present invention is directed to novel compounds that function as immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases, to novel adjuvant formulations which include at least one of the adjuvant compounds of the invention, to novel immunostimulatory compositions which comprise an antigen and at least one of the adjuvant compounds of the invention, and to methods for the immunization of an animal by co-administration of a compound of the invention with an antigen against which the animal is to be immunized.
FI20011593A 1999-02-01 2001-07-31 Immunological Adjuvant Compound FI120689B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11813199P 1999-02-01 1999-02-01
US11813199 1999-02-01
US0002755 2000-02-01
PCT/US2000/002755 WO2000044758A1 (en) 1999-02-01 2000-02-01 Immunological adjuvant compound

Publications (2)

Publication Number Publication Date
FI20011593A true FI20011593A (en) 2001-07-31
FI120689B FI120689B (en) 2010-01-29

Family

ID=22376670

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20011593A FI120689B (en) 1999-02-01 2001-07-31 Immunological Adjuvant Compound

Country Status (21)

Country Link
US (1) US6290973B1 (en)
EP (2) EP1439184B1 (en)
JP (1) JP4698027B2 (en)
KR (1) KR100711561B1 (en)
AT (2) ATE269341T1 (en)
AU (2) AU768574B2 (en)
BR (1) BRPI0007936B8 (en)
CA (1) CA2361582C (en)
DE (2) DE60044570D1 (en)
DK (1) DK1147117T3 (en)
ES (2) ES2223464T3 (en)
FI (1) FI120689B (en)
HK (2) HK1070372A1 (en)
HU (1) HU226869B1 (en)
IL (3) IL144671A0 (en)
MX (1) MXPA01007760A (en)
NO (1) NO329111B1 (en)
NZ (1) NZ513259A (en)
PT (1) PT1147117E (en)
WO (1) WO2000044758A1 (en)
ZA (1) ZA200106487B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
EP1177187B1 (en) * 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
EP1307466B1 (en) * 2000-07-31 2005-11-16 Eisai Co., Ltd. Immunological adjuvant compounds
KR100947751B1 (en) * 2001-01-23 2010-03-18 아벤티스 파스퇴르 Multivalent meningococcal polysaccharide-protein conjugate vaccine
KR100902171B1 (en) * 2001-03-08 2009-06-10 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Facially amphiphilic polymers as anti-infective agents
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
EP1513853A2 (en) * 2002-05-24 2005-03-16 Neopharm, Inc. Cardiolipin compositions, methods of preparation and use
EA200401565A1 (en) * 2002-05-24 2005-04-28 Неофарм, Инк. METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS)
JP3900343B2 (en) * 2002-09-05 2007-04-04 株式会社トリケミカル研究所 (RO) (R′O) (R ″ O) M = O Production Method
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
CN102432511B (en) * 2003-03-17 2016-06-08 宾夕法尼亚州大学理事会 Facially amphilic polymers and oligomer and application thereof
ES2596553T3 (en) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Immunogenic compositions based on microparticles comprising adsorbed toxoid and an antigen containing a polysaccharide
JP2007514648A (en) 2003-10-24 2007-06-07 エーザイ株式会社 Compounds and methods for treating diseases and conditions associated with Toll-likereceptor2
FR2863890B1 (en) * 2003-12-19 2006-03-24 Aventis Pasteur IMMUNOSTIMULATING COMPOSITION
KR20070001959A (en) * 2004-01-23 2007-01-04 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Facially amphiphilic polyaryl and polyarylalkynyl polymers and olygomers and uses thereof
JP2008531585A (en) * 2005-02-25 2008-08-14 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Surface amphiphilic polymers and oligomers, their compositions and their use in cancer treatment methods
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
EP1874342B1 (en) 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
EP1910387B1 (en) * 2005-06-30 2016-11-16 Eisai R&D Management Co., Ltd. Compounds for preparing immunological adjuvant
WO2009076158A1 (en) 2007-12-07 2009-06-18 Novartis Ag Compositions for inducing immune responses
EP2565179A1 (en) * 2007-12-18 2013-03-06 Eisai R&D Management Co., Ltd. Reagents and methods for the beta-keto amide synthesis of a synthetic precursor to immunological adjuvant e6020
EP2298344B1 (en) 2008-06-04 2016-08-17 The Chemo-Sero-Therapeutic Research Institute Use of inactivated japanese encephalitis virus particle as adjuvant
WO2013043580A2 (en) 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
WO2013166431A1 (en) 2012-05-03 2013-11-07 Beth Isreal Deaconess Medical Center, Inc. Lipids that increase insulin sensitivity and methods of using the same
CA2942709C (en) 2013-03-15 2021-04-06 Beth Israel Deaconess Medical Center, Inc. Lipids that increase insulin sensitivity and methods of using the same
AU2014300503B2 (en) 2013-06-28 2018-11-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
EP3237374A4 (en) 2014-12-23 2018-04-25 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
TW201735952A (en) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 Amino acid and peptide conjugates and conjugation process
US11013711B2 (en) 2016-06-10 2021-05-25 Beth Israel Deaconess Medical Center, Inc. Fatty acid esters of hydroxy fatty acids (FAHFAs) for use in the treatment of type 1 diabetes
CA3165957A1 (en) 2020-01-24 2021-07-29 Thomas K. EQUELS Methods, compositions, and vaccines for treating a virus infection
CN113307824B (en) * 2021-04-26 2022-05-27 浙江大学 Amphiphilic material and application thereof in preparation of liposome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2583892A (en) 1991-09-11 1993-04-05 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
EP0732936B1 (en) * 1993-12-09 2000-03-29 Heinrich Exner Adjuvant for antigens, process for producing the same and its use
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6180111B1 (en) * 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof

Also Published As

Publication number Publication date
EP1147117A1 (en) 2001-10-24
EP1147117B1 (en) 2004-06-16
HK1070372A1 (en) 2005-06-17
ZA200106487B (en) 2002-08-07
BR0007936A (en) 2002-04-09
EP1439184A1 (en) 2004-07-21
DE60011571T2 (en) 2005-08-18
BR0007936B1 (en) 2015-03-10
AU768574B2 (en) 2003-12-18
IL144671A (en) 2006-07-05
IL144671A0 (en) 2002-05-23
HUP0105473A2 (en) 2002-04-29
HK1043132A1 (en) 2002-09-06
US6290973B1 (en) 2001-09-18
HU226869B1 (en) 2010-01-28
DE60011571D1 (en) 2004-07-22
PT1147117E (en) 2004-10-29
DE60044570D1 (en) 2010-07-29
CA2361582C (en) 2010-04-06
AU2004201147A1 (en) 2004-04-22
ATE269341T1 (en) 2004-07-15
NZ513259A (en) 2004-05-28
JP4698027B2 (en) 2011-06-08
AU2867500A (en) 2000-08-18
NO20013749L (en) 2001-09-25
NO20013749D0 (en) 2001-07-31
BRPI0007936B8 (en) 2021-05-25
FI120689B (en) 2010-01-29
ES2347428T3 (en) 2010-10-29
HUP0105473A3 (en) 2003-11-28
ES2223464T3 (en) 2005-03-01
KR20010101912A (en) 2001-11-15
AU2004201147B2 (en) 2008-04-03
WO2000044758A1 (en) 2000-08-03
IL174413A0 (en) 2009-02-11
JP2002535411A (en) 2002-10-22
MXPA01007760A (en) 2003-06-24
ATE471328T1 (en) 2010-07-15
HK1043132B (en) 2005-04-01
DK1147117T3 (en) 2004-10-25
EP1439184B1 (en) 2010-06-16
KR100711561B1 (en) 2007-04-27
NO329111B1 (en) 2010-08-30
CA2361582A1 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
DK1147117T3 (en) Immunological adjuvant compounds
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
ATE397942T1 (en) ADJUVANT COMPOSITIONS FOR INCREASE THE IMMUNE RESPONSE TO POLYNUCLEOTIDE-BASED VACCINES
MXPA04002490A (en) Interleukin-12 as a veterinary vaccine adjuvant.
PT1104306E (en) CPG COMPOSITIONS AND SAPONIN ADJUVANTS AND THEIR METHODS
WO2002013857A8 (en) A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
NZ596870A (en) Vaccine compositions comprising a saponin adjuvant
IS4518A (en) New vaccine formulation
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
AU2003288510A1 (en) Immunizing fish against viral infection
EA200800917A1 (en) ADJUVANTA FOR VACCINES
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
DK0626008T3 (en) Vaccine containing as an adjuvant acemannan
MX2009000717A (en) Vaccine composition and immunization method.
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
WO2004043286A3 (en) Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
PL341541A1 (en) Isolated strains of staphyloccoccus aureus and vaccines prepared of them
WO2006109186A3 (en) Early endosome neutralising compouds as vaccine adjuvants
WO2003040163A3 (en) Immunomodulating saponins, a method for their preparation and their use for vaccines

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: EISAI R&D MANAGEMENT CO., LTD.

Free format text: EISAI R&D MANAGEMENT CO., LTD.

FG Patent granted

Ref document number: 120689

Country of ref document: FI

MA Patent expired